-
HIV/AIDS activists in Zimbabwe have welcomed the government's move to address the problem of HIV drug resistance by introducing third-line antiretroviral drug (ARVs). But it remains unclear how the cash-strapped government will finance this, as procuring the drugs will invariably be expensive and could divert resources away from other HIV treatment efforts.
12 March 2013 | IRIN Plus News
-
It is time to create a new paradigm to break the vicious cycle of single drug access that has failed these patients.
04 December 2012 | GMHC Treatment Issues
-
HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.
13 November 2012 | International AIDS Society
-
The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regimen they prescribe to HIV-infected individuals.
)
14 September 2012 | Science Daily
-
In a randomized trial, switching away from the booster drug allowed treatment-experienced patients to keep HIV under control and reduced toxicity, according to David Wohl, MD, of the University of North Carolina in Chapel Hill.
13 September 2012 | MedPage Today
-
The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare's investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for therapy.
09 March 2012 | The Body
-
Adding maraviroc (Selzentry or Celsentri) to a suppressive antiretroviral
regimen may help promote CD4 T-cell recovery in a subset of patients who
experience poor immunological response to treatment, according to 2 studies
presented at the 13th European AIDS Conference (EACS 2011) this month in
Belgrade.
27 October 2011 | HIVandhepatitis.com
-
The proportion of HIV patients who are able to suppress the virus
despite extensive drug resistance nearly tripled over a 10-year period,
researchers reported.
10 October 2011 | MedPage Today
-
About 750 HIV patients requiring advanced treatment in the state
are forced to go without life-saving second-line anti-retroviral therapy
(ART) drugs which are in short supply.
07 August 2011 | Times of India
-
Most of us built resistance as we joined study after study that exposed us to
functional monotherapy. In fact, I consider many of us who have been struggling
with multiple drug resistance to be wounded soldiers from a time when we were
recruited into studies we joined out of desperation to access a new drug.
04 May 2011 | The Body
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Treatment as prevention – free webinar 20 March 2013As
part of its European HIV prevention work, NAM is collaborating...
Microbicides research – free webinar 22 February 2013As
part of its European HIV prevention work, NAM is collaborating...
HIV treatment update – Winter 2013 21 February 2013The new edition of HIV treatment update (HTU) is on...